Holen Sie sich die Stockscreener-App
24.66
0.04%
0.01
Handel nachbörslich:
24.74
0.08
+0.32%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$24.65
Offen:
$24.59
24-Stunden-Volumen:
140.35M
Relative Volume:
2.62
Marktkapitalisierung:
$140.21B
Einnahmen:
$63.83B
Nettoeinkommen (Verlust:
$10.77B
KGV:
13.12
EPS:
1.8799
Netto-Cashflow:
$12.44B
1W Leistung:
-0.44%
1M Leistung:
-9.90%
6M Leistung:
+1.90%
1J Leistung:
-12.21%
1-Tages-Spanne:
$24.41
$24.75
1-Wochen-Bereich:
$24.15
$24.78
52-Wochen-Spanne:
$20.91
$28.14
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.66 | 140.15B | 63.83B | 10.77B | 12.44B | 1.8799 |
|
LLY
Lilly Eli Co
|
896.53 | 772.28B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.26 | 455.04B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
211.96 | 385.18B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
123.86 | 237.53B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
82.49 | 214.76B | 63.99B | 19.05B | 14.72B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Why Pfizer Can Still Prevail in the Obesity Fight With Novo NordiskWSJ - The Wall Street Journal
Pfizer accuses Novo Nordisk of anticompetitive plot to stall Metsera deal in lawsuit - Yahoo! Finance Canada
AMD, Uber, Pfizer earnings on deck; ADP job data: What to Watch - Yahoo Finance
Pfizer Hits Novo Nordisk In Fed. Court Over $9B Metsera Deal - Law360
Pfizer Sues Novo, Metsera for Second Time in Brewing Deal War - Bloomberg.com
Pfizer Reports Earnings on Tuesday. What to Expect. - Barron's
Stock Movers: Cisco, Disney, Pfizer - Bloomberg.com
Pfizer Lawsuits Allege Novo Nordisk’s Bid to Buy Obesity Biotech Metsera is Anticompetitive, Illegal - MedCity News
Pfizer Files Lawsuits Against Metsera and Novo Nordisk - Pharmaceutical Executive
Market Voices: Pfizer-Novo Nordisk legal battle; Trump on Zhao pardon - Seeking Alpha
What's Up With The Rise In Eli Lilly Stock Today? - Benzinga
Pfizer sues to block Novo Nordisk bid for obesity drug maker Metsera - The Business Journals
Did Novo Nordisk Just Say "Checkmate" to Pfizer? - Yahoo Finance
Metsera, Inc. Responds to Pfizer’s Litigation Claims - TipRanks
Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo - Investor's Business Daily
Metsera rejects Pfizer litigation as attempt to lower acquisition price - Investing.com
Pfizer files second lawsuit against Metsera, Novo Nordisk - Global Banking | Finance | Review
Pfizer sues Novo, Metsera for second time in brewing deal war - Crain's New York Business
Metsera issues statement regarding Pfizer litigation and proposed acquisition By Investing.com - Investing.com UK
Pfizer Q3 Earnings Preview: Results to test recovery hopes amid TrumpRx deal, Metsera dispute (PFE:NYSE) - Seeking Alpha
Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera - The Wall Street Journal
Pfizer Aligns With Trump on Drug Pricing In Its Bid for Biotech Metsera - Barron's
Pfizer Files Antitrust Lawsuit Against Metsera, Its Controlling Stockholders And Novo Nordisk - Nasdaq
Jim Cramer on Pfizer: “We’ll Find Out if Pfizer’s Going to Be More of a Stock and Less of a Bond Equivalent” - MSN
Metsera to address Pfizer's litigation in court - MarketScreener
Pfizer files second lawsuit against Metsera, Novo Nordisk By Reuters - Investing.com
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook - ts2.tech
Pfizer (PFE) Files Lawsuit Against Novo Nordisk Over Metsera Bid - GuruFocus
Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle - Benzinga
Pfizer files second lawsuit to block Novo Nordisk’s $9bn Metsera bid - Financial Times
Pfizer sues Novo Nordisk and Metsera once againbid considered to restrict competition - MarketScreener
Pfizer files second lawsuit in fight over Metsera - Axios
United States Vitiligo Forecast Report 2025: A $320+ Million Market by 2033 Featuring Incyte, BMS, Clinuvel Pharmaceuticals, Astellas Pharma, Baxter, Pfizer, Dr. Reddy's LaboratoriesResearchAndMarkets.com - Business Wire
How To Earn $500 A Month From Pfizer Stock Ahead Of Q3 Earnings - Benzinga
Pfizer files fresh US lawsuit against Novo Nordisk bid for Metsera - MLex
Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk - Caledonian Record
Pfizer hits Novo Nordisk and Metsera with lawsuit amid bidding war - Yahoo Finance
Pfizer Inc. $PFE Shares Purchased by Machina Capital S.A.S. - MarketBeat
Intellectus Partners LLC Sells 32,016 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Gains Early FTC Clearance for Metsera Acquisition - Zacks Investment Research
Torray Investment Partners LLC Raises Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Sues To Block Metsera’s Move Toward Novo Nordisk Deal - Finimize
Metsera, Inc. Responds to Pfizer Litigation - TradingView
Pfizer Inc. $PFE Shares Sold by TIAA Trust National Association - MarketBeat
United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key PlayersNovartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb - Yahoo Finance
Meet the 7% Yield Dividend Stock That Could Soar in 2026 - Yahoo Finance
1 Incredible Reason to Buy Pfizer Stock (PFE) in November - Yahoo Finance
U.S. Vasopressin Market Poised for Transformation with - openPR.com
The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit - Stocktwits
Pfizer sues Novo Nordisk and Metsera - MarketScreener
Pfizer (PFE) Sues Over Metsera Acquisition Bid - GuruFocus
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):